[Clinical considerations on the use of a new synthetic androgen, Calusterone, in the treatment of advanced breast cancer].
Results with a new synthetic androgen (Calusterone) in the management of 22 cases of advanced breast cancer are presented. Reference is made to the doses employed, the therapeutic results observed, and the side-effects caused by the drug. By comparison with the literature data, a partial response to treatment was observed in 47% of the series.